biomarker-trends-header.png

Fail Early, Fail Fast - And Increase Likelihood-of-Approval

What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how it affects the industry.

Chart of the Week: Phase 3 LOA Vs Biomarker Coverage Percent

This week’s Chart of the Week demonstrates recent research on the correlation between the Biomarker Coverage Percent in a company's pipeline and the Company's Phase 3 Likelihood of Approval. This chart depicts how as a company increases their number of trials utilizing biomarkers, they will also ...

Chart of the Week: Phase 3 LOA Vs Precision Medicine Score

This week’s Chart of the Week attempts to communicate the correlation between a Company's Precision Medicine Score and the Company's Phase 3 Likelihood of Approval (LOA). This chart depicts how as a company increases their Precision Medicine Score, they will also see an increase in their likelihood ...

Chart of the Week: Missed Biomarker Information Without Comprehensive Synonyms

This week’s Chart of the Week attempts to communicate recent research on the percent of results you are missing in your clinical information searches (e.g. pubmed, clinicaltrials.gov, etc) without utilizing  target and synonym technologies like in BiomarkerBase. This chart depicts how many relevant ...

Chart of the Week: Biopharma Players in Alzheimers

We've published a few "graphs" illustrating topics interesting to us.  Last month published a graph showing Celgene's biomarker and trial activities.  More recently we published a biomarker and trial landscape graph for Alzheimer's disease. Because Alzheimer's is getting a lot of attention at the ...

   

March

Webinar: 

Pharmacovigilance and Safety Biomarkers

RECORDING
New Call-to-action
FREE REPORT

Subscribe for Updates

Download our Free IVD Trends Report